Exosome-derived noncoding RNAs: Function, mechanism, and application in tumor angiogenesis

Kangkang Yang,1 Quanbo Zhou,1 Bingbing Qiao,1 Bo Shao,1,2 Shengyun Hu,1 Guixian Wang,1 Weitang Yuan,1 and Zhenqiang Sun1,2

Exosomes are extracellular vesicles released by various cell types that perform various biological functions, mainly mediating communication between different cells, especially those active in cancer. Noncoding RNAs (ncRNAs), of which there are many types, were recently identified as enriched and stable in the exocrine region and play various roles in the occurrence and progression of cancer. Abnormal angiogenesis has been confirmed to be related to human cancer. An increasing number of studies have shown that exosome-derived ncRNAs play an important role in tumor angiogenesis. In this review, we briefly outline the characteristics of exosomes, ncRNAs, and tumor angiogenesis. Then, the mechanism of the impact of exosome-derived ncRNAs on tumor angiogenesis is analyzed from various angles. In addition, we focus on the regulatory role of exosome-derived ncRNAs in angiogenesis in different types of cancer. Furthermore, we emphasize the potential role of exosome-derived ncRNAs as biomarkers in cancer diagnosis and prognosis and therapeutic targets in the treatment of tumors.

INTRODUCTION

Tumors are characterized by unlimited replication, nutritional self-sufficiency, and abnormal cellular energy metabolism. This extreme and disordered growth environment depends on angiogenesis.1 Excessive angiogenesis is a key tumorigenic phenomenon, and it correlates with tumor initiation, malignant progression, and poor prognosis.3 In recent years, the studies of tumor microenvironments (TME) have provided a new understanding of tumor growth and new ways to treat cancer.4 Among the TME, exosomes derived from many cells and the substances they carry are an important integral component. They circulate freely in vivo and accumulate in TME and have been recognized as a new contributor to angiogenesis.4

Some studies have shown that exosomes play an important role in tumorigenesis, proliferation, metastasis, and invasion;5–8 thus, the extensive and in-depth studies of tumor angiogenesis are inseparable from exosomes and their carriers, especially noncoding RNAs (ncRNAs). ncRNAs constitute a large class of molecules that are not thought to encode proteins and are divided into microRNAs (miRNAs), long noncoding RNAs (lncRNAs), circular RNAs (circRNAs), small nucleolar RNAs (snRNAs), small nucleolus RNAs (snoRNAs), PIWI-interacting RNAs (piRNAs), ribosomal RNAs (rRNAs), and transfer RNAs (tRNAs) according to their transcriptional length;9,10 ncRNAs account for up to 98%–99% of the human genome, perform many basic regulatory functions in eukaryotes, and even play roles in abnormal cell functions associated with cancer progression and metastasis.11 Numerous studies investigating the unique characteristics and vascular endothelial cell function of exosome-derived ncRNAs have shown that they play an important role in tumor angiogenesis.12 For example, miR-210 released by exosomes secreted by metastatic cancer cells mediated by neutral sphingomyelinase 2 (nSMase2) promoted angiogenesis in the TME by targeting endothelial cells and inhibiting the expression of the specific target gene ephrin-A3.13 This finding indicates that exosome-derived ncRNAs may potentially become new biomarkers and therapeutic targets for cancer therapy. Therefore, exosome-derived ncRNAs have received increasing attention in exosome research.

In this review, we discuss the basic characteristics of exosomes and exosome-derived ncRNAs and the functional role of exosome-derived ncRNAs in cancers. In particular, we summarize and emphasize the mechanism and clinical application value of exosome-derived ncRNAs in tumor angiogenesis.

EXOSOME-DERIVED ncRNAs IN CANCERS

Exosomes are 30- to 150-nm extracellular vesicles secreted by mammalian cells14 resulting from multivesicular endosomes or multivesicular bodies fusing into the plasma membrane and being secreted out of cells under the condition of intercellular communication and regulation between adjacent and distant cells.15,16 Numerous

https://doi.org/10.1016/j.omtn.2022.01.009.

Correspondence: Zhenqiang Sun, PhD, Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
E-mail: fccunzq@zzu.edu.cn

Correspondence: Weitang Yuan, PhD, Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
E-mail: yuanweitang@zzu.edu.cn
studies have shown that exosomes are excreted from many types of cells (such as tumor cells, B lymphocytes, stem cells, dendritic cells (DCs), platelets, etc.) and circulate in bodily fluids (such as blood, urine, saliva, etc.). The contents of exosomes are complex and include nucleic acids, proteins, and lipids. Exosomes are highly heterogeneous due to the different compositions of their contents, which indicate the source of the cells that produce them. A clinical study has proved the safety of exosomes in the treatment of cancers by inoculating melanoma patients with vaccination based on dendritic cell-derived exosomes. Exosomes activate signal transduction pathways by directly binding their surface membrane molecules to receptor target cells and are internalized into the target cells through the combination of the lipid membrane and the target cell membrane; this process is realized by transmembrane proteins and extracellular matrix proteins. For example, exosomes can be located on the extracellular matrix and together with matrix vesicles as the initial location of mineralized nodules. However, the underlying mechanisms remain unclear. The role of exosomal contents internalized into cells has been extensively studied. For example, exosomes can affect tumor angiogenesis through these contents. A study noted that IL-8 and platelet-derived growth factor (PDGF), which are carried by exosomes originating from glioblastoma multiforme cells of hypoxic brain tumors, are considered angiogenic stimulating molecules. Among the contents of exosomes, ncRNAs, such as miR-9, are the most studied. Exosomes originating from melanoma cells have been internalized through endothelial cells (ECs), and miR-9 derived from exosomes promotes angiogenesis and metastasis by activating the Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway. ncRNAs regulate normal cell growth and apoptosis and play an important role in abnormal cells, such as tumor cells. It has been confirmed that ncRNAs can not only act as gene expression and splicing regulators but also serve as epigenetic controllers and provide guidance for chromatin-modification complexes. Some ncRNAs are thought to function by being packaged in exosomes and transferred to receptor cells. With the rapid development of RNA sequencing technology and bioinformatics, new information regarding the role of exosome-derived ncRNAs in cancer has gradually emerged. These molecules play a vital role in cancer. Exosome-derived ncRNAs can not only promote cell proliferation and migration, the epithelial-mesenchymal transformation (EMT), tumor proliferation, angiogenesis and metastasis but also participate in tumor immune escape, promote tumorigenesis and even cause tumor cells to acquire chemical resistance, leading to tumor drug resistance. For example, exosome-derived miR-210 promotes tumor angiogenesis through endothelial cell uptake and the inhibition of specific target genes highly expressed in breast cancer. Studies have increasingly demonstrated that miRNAs and IncRNAs are regulators of homeostasis and cellular signal transduction and play an important role in tumor progression and metastasis. Tumor angiogenesis is also an important part of the TME that can regulate the occurrence and development of tumors.

TUMOR ANGIOGENESIS

Angiogenesis is the complex process of generating new capillaries from existing blood vessels and usually includes the following steps: vascular endothelial growth factor (VEGF)-stimulating ECs, enzymatic degradation of the vascular basement membrane, proliferation, migration, and germination of vascular endothelial cells, branching, and tube formation. Under physiological conditions in normal adults, the net balance between proangiogenic factors and antiangiogenic factors controls the process of angiogenesis, and blood vessels remain static and rarely form new branches. Tumors secrete various substances to break this balance and induce pathological angiogenesis, which eventually develops into a complex, mature vascular system. This system provides the tumor with the necessary nutrients and oxygen to promote tumor growth and causes the tumor cells to leave the original site of the tumor and spread to distant organs through the blood. Hypoxia is the main force driving tumor angiogenesis, and VEGF plays a key role in tumor angiogenesis by enhancing all the steps of angiogenesis. Hypoxia is the most typical and important feature in the TME and is a marker of malignant tumors. Due to the excessive consumption of oxygen by tumor cell proliferation coupled with tumor-related leakage and a disordered vascular system, tumors cause not only the acute flux of oxygen tension but also the diffusion-limited area of low oxygen levels, leading to hypoxia. Hypoxia triggers proteomic changes in tumor cells and stromal cells, further promoting the aggressiveness and poor survival of tumor cells, while leaky blood vessels cause these cells to metastasize remotely. However, during tumor spread, the oxygen and nutrients necessary for solid tumor growth provided by adjacent capillaries are insufficient; thus, tumor cells must induce new angiogenesis to ensure the supply of oxygen and nutrients. These abnormal blood vessels produce tumor blood vessels but cannot effectively restore the blood supply and further promote temporal and spatial changes in oxygen transport, thereby aggravating the hypoxic phenotype of the tumor. Consequently, the tumor survives and drives tumor growth under these adverse growth conditions.

Hypoxia induces a stress reaction between the tumor and the oxygen-monitoring mechanism, which promotes the hypoxia signaling pathway and changes the transcription of many genes. This pathway is mainly regulated by hypoxia-inducible factors (HIFs; HIF-1α, HIF-2α, and HIF-3α). HIF-1α induces the expression of angiogenic proteins, such as VEGF, epidermal growth factor, PDGF, hepatocyte growth factor (HGF), and fibroblast growth factor (FGF). Studies have increasingly shown that in a hypoxic environment the cells in the TME induce ncRNA overexpression, and ncRNAs are released by exosomes and participate in tumor angiogenesis by reacting with ECs and other angiogenic cells, thereby affecting tumor progression (Figure 1). For example, exosome-derived miR-135b from myeloma cells enhances tumor angiogenesis through the HIF-FIH (factor hypoxia-inducible factor) signaling pathway. In addition, a study found that in an anoxic environment
tumor cells transfer miR-494 to ECs through exosomes by targeting phosphatase and tensin homolog (PTEN) and then activate the Akt/eNOS pathway, leading to a HIF-1α-mediated mechanism to enhance EC migration and promote angiogenesis and tumor growth.67

ROLE OF DIFFERENT CELL-DERIVED EXOSOMES IN TUMOR ANGIOGENESIS

Most cells in the body produce exosomes, which play an important role in the process of transmitting biological information to the target by carrying and releasing different types of contents.68 Studies have shown that the characteristics and functions of cell-derived exosomes are involved in various situations, including diseases of the central nervous system, myocardial ischaemia/circulation injury, liver and kidney injury, the regulation of tumor markers, and the induction of angiogenesis and metastasis.69 Among these functions, pathological angiogenesis represents a sign of tumor progression, and exosomes derived from various cells in the TME, especially exosome-derived ncRNAs, play an important role in regulating this process.70 Among these processes, exosomes secreted by tumor cells, stem cells (SCs), and tumor-associated macrophages (TAMs) play a role in regulating the angiogenesis of ECs17 (Figure 2).

Tumor-derived exosomes

Tumor-derived exosomes (TEXs) play an important role in tumor growth, angiogenesis, immune regulation, metastasis, and drug resistance.71 Especially in the early stage of tumor development, TME pressure or hypoxia stimulates tumor cells to increase exosome secretion.72 TEXs circulate freely in bodily fluids, accumulate in the TME, and interact with ECs and other tissues or immune cells to accelerate tumor angiogenesis. Studies have increasingly confirmed that TEXs play a key role in angiogenesis.73 Under hypoxia, overexpressed TEXs are absorbed by and internalized into ECs. EGFR transferred to ECs may be involved in the molecular mecha-

Figure 1. Role of hypoxia-related exosome-derived ncRNAs in tumor angiogenesis

(A) Hypoxia induces a large release of exosome-derived ncRNAs. (B) Exosome-derived ncRNAs act on ECs. (C) Exosome-derived ncRNAs react with substances in ECs. (D) EC proliferation promotes angiogenesis. The green arrow indicates stimulatory modification; the red “T” indicates inhibitory modification.

nism driving EC reprogramming, which activates ECs to produce VEGF and upregulates VEGFR2 signal transduction.74 TEXs cause the loss of cadherin and β-catenin on the surface of ECs and promote the movement of ECs.75 In addition, exosomes carrying tetraspanin Tspan8 induce transcriptional changes in ECs, resulting in the increased expression of angiogenic genes and increased proliferation of ECs.76 ECs begin to secrete cytokines and growth factors after TEX uptake, which stimulates pericytes through the PI3K/Akt pathway.77 In addition, some studies confirmed that TEXs transfer the components of the Notch pathway to ECs to stimulate new angiogenesis and establish a new vascular network.78 Increasing evidence suggests that TEXs affect tumor angiogenesis mainly through a series of reactions, such as ncRNAs acting on ECs. For example, TEXs secreted by lung cancer cells increase the expression and secretion of VEGF by transferring miR-21 to ECs and stimulating the angiogenesis of ECs in vitro.44

SC-derived exosomes

SCs refer to undifferentiated cells. SCs related to tumor progression are usually divided into the following two phenotypes: adult stem cells and cancer stem cells (CSCs).79 Mesenchymal stem cells (MSCs) are among the most widely studied adult stem cells.80 Exosomes secreted by MSCs and CSCs, as the main regulators of TME cell signaling, also play an important role in tumor angiogenesis.81

How MSC-derived exosomes affect tumor angiogenesis remains controversial. Interestingly, according to current studies, exosomes derived from MSCs have been shown to exert mainly antiangiogenic and antitumorigenic effects. Especially in recent years, numerous experiments investigating the release of ncRNAs confirmed these effects.82 The overexpression of exosome-derived miR-16 and miR-100 from MSCs downregulates the expression of VEGF in breast cancer cells, thereby inhibiting angiogenesis and tumor growth in vivo and in vitro.80,82

CSCs are regarded as the basic cells in heterogeneous tumor tissue, and their secreted exosomes become effective TME regulators that affect tumor angiogenesis, especially the self-renewing regulatory ncRNAs they carry, which play a key role.83 Exosomes secreted by CD90+ hepatoma cells, which are defined as CSCs, upregulate
VEGF by passing overexpressed lncRNAH19 to ECs to promote angiogenesis and tumor growth.84

TAM-derived exosomes

Macrophages have two phenotypes with opposite functions, namely, the proinflammatory, antibacterial, and anti-angiogenic M1-like phenotype and the protumour and proangiogenic M2-like phenotype, and TAMs are considered the latter.85 In the process of tumor progression, the TME leads to hypoxia, and TAMs release factors related to tumor growth, immunosuppression, and angiogenesis through exosomes.86 TAM-derived exosomes are important regulators of invasiveness in pancreatic ductal adenocarcinoma (PDAC). TAM-derived exosomes are rich in miR-501-3p, and when cocultured with PDAC cells in animal experiments, the migration and invasive ability of PDAC cells are enhanced, and the expression of VEGFA, VEGFR2, angiopoietin-2 (ANG2), and PIGF is significantly upregulated, promoting tumor angiogenesis.87

TYPES OF EXOSOME-DERIVED ncRNAs IN TUMOR ANGIOGENESIS

Studies have shown that exosome-derived ncRNAs are involved in many aspects of tumor progression and play an important role in tumor angiogenesis. In recent years, an increasing number of studies confirmed that ncRNAs, especially miRNAs, lncRNAs, and circRNAs, are loaded into exosomes to target the TME or distant cells to directly or indirectly regulate angiogenesis by important angiogenic factors and signaling molecules (Table 1).

miRNAs

miRNAs are highly conserved posttranscriptional single-stranded ncRNAs with lengths of 21 to 25 nucleotides that regulate gene expression. miRNAs are abundant ncRNAs in exosomes.128 In recent years, several exosome-derived miRNAs were shown to affect different targets in the tumor angiogenesis pathway and regulate tumor angiogenesis by directly or indirectly acting on proangiogenic factors or antiangiogenic factors, such as VEGF, HIF, PDGF, and reactive oxygen species (ROS), to cause tumor progression or stagnation.124 For example, exosome-derived miR-21 is overexpressed in lung cancer, glioma, and head and neck cancer to promote tumor angiogenesis and induce tumor progression.44,90–92 Other studies found that miR-210 is highly expressed in HCC cells. SMAD4 is a tumor suppressor that can mediate the TGF-β signaling pathway. Interestingly, both in vitro and in vivo studies have shown that miR-210 is packaged into exosomes secreted by HCC cells and transferred to ECs, and then, these mature miR-210 inhibited the expression of SMAD4 and STAT6 in ECs to achieve HCC angiogenesis.106

lncRNAs

lncRNAs constitute a large RNA subgroup with a size of more than 200 nucleotides with no or limited protein-coding potential.125–127 lncRNAs play an important role in the regulation of basic pathological and biological processes. In recent years, lncRNAs have been shown to mediate tumor angiogenesis through exosomes under the regulation of VEGF, matrix metalloproteinase (MMP), hypoxia, stem cells, miRNA, and other conditions and are believed to participate in the “angiogenesis switch” as a key regulatory factor.128 Among them, lncRNAs and lincRNAs are closely related to the regulation of tumor angiogenesis. Some studies revealed that the lincRNAs CCAT2 and POU3F3 and the lncRNA HOTAIR were overexpressed in exosomes secreted by glioma. By acting on target cells, lncRNAs increase the expression of VEGF, TGF-β and FGF, thereby promoting angiogenesis and accelerating tumor progression. Simultaneously, lncRNAs upregulate the expression of Bcl-2 and inhibit Bax and caspase-3, thereby inhibiting hypoxia-induced apoptosis.92,115,117 Therefore, lncRNAs promote angiogenesis through different mechanisms to create a favourable microenvironment for tumor growth and metastasis.

circRNAs

circRNAs are naturally occurring and highly conserved single-stranded closed-loop molecules. Due to the lack of 5’ and 3’ ends and poly(A) tails, circRNAs resist cleavage by RNA enzymes;
Table 1. Exosome-derived ncRNAs in tumor angiogenesis

| Exosome-derived ncRNA type | Tumor type | Study cell line | Source cell type | Target cell | Regulatory mechanism | Reference |
|----------------------------|------------|-----------------|------------------|-------------|----------------------|-----------|
| miR-9                      | Glioma     | A172, U87, and U251 | Tumor           | HUVEC       | Upregulation of VEGF and HIF-1α | Chen et al. 88 |
| miR-9                      | Melanoma   | SK23            | Tumor           | EC          | JAK-STAT pathway     | Zhuang et al. 89 |
| miR-9                      | NPC        | 5-8F and CNE1   | Tumor           | HUVEC       | Upregulation of MDK and the PDK/AKT pathway | Lu et al. 89 |
| miR-16                     | BC         | MSC             | SC              | BC cell     | Downregulation of VEGF | Lee et al. 82 |
| miR-21                     | CML        | K562 and LAMA84  | Tumor           | HUVEC       | Downregulation of RhoB | Taverna et al. 90 |
| miR-21                     | LC         | SV40            | Tumor           | HUVEC       | Upregulation of VEGF | Liu et al. 44 |
| miR-21                     | HNSCC      | FaDu            | Tumor           | CD14+ human monocytes | Increase the expression of M2 polarization of TAMs markers | Hsieh et al. 51 |
| miR-21                     | Glioblastoma | U-251         | SC              | HUVEC       | Upregulation of VEGF | Sun et al. 52 |
| miR-23a                    | NPC        | CNE2            | Tumor           | HUVEC       | Inhibition of TSGA10 expression | Bao et al. 93 |
| miR-23b                    | BC         | MCF7            | Tumor           | EC          | Inhibition of PLAU, AMOTL1,NRP1, and ETS2 expression | Hannafon et al. 64 |
| miR-23b                    | LC         | SK562           | Tumor           | EC          | Inhibition of KLF2 and KLF4 expression | Zeng et al. 35 |
| miR-32-5p                  | CRC        | SW480, NCM460, and HCT116 | Tumor           | EC          | PI3K/AKT pathway | Fu et al. 77 |
| miR-100                    | BC         | MDA-MB-231 and MCF-7 | SC              | BC cell     | Targets integrin-α5 | Umezlu et al. 96 |
| miR-130a                   | GC         | SGC-7901        | Tumor           | HUVEC       | Downregulation of VEGF | Tomasetti et al. 37 |
| miR-135b                   | MM         | RPMI8226, KMS-11 and U266 | Tumor           | HUVEC       | Downregulation of c-MYB | Yang et al. 39 |
| miR-141-3p                 | EOC        | SKOV-3          | Tumor           | HUVEC       | Inhibition of FIH-1 | Umezlu et al. 66 |
| miR-141-3p                 | LARC       | -               | Not mentioned   | Not mentioned | PI3K/Akt pathway | Meltzer, el. 101 |
| miR-142-3p                 | LAC        | H1437 and H2073 | Tumor           | HMEC        | Inhibition of TGFβR1 | Lawson et al. 101 |
| miR-148a                   | OS         | SAOS-2, MG-63, and U-2 | Tumor           | HUVEC       | Upregulation of VEGFA | Raimondi et al. 102 |
| miR-155                    | BL         | Raji            | Tumor           | ARPE-19     | Uregulation of VEGFA | Yoon et al. 103 |
| miR-155-5p                 | Melanoma   | NIH/3T3         | Tumor           | CAF         | Downregulation of SOCS1 activates the JAK2/STAT3 pathway | Zhou et al. 104 |
| miR-205                    | OC         | HO-8910         | Tumor           | EC          | PTEN-Akt pathway | He et al. 105 |
| miR-210                    | CML        | K562            | Tumor           | EC          | Downregulation of EPNA3 | Tadokoro et al. 74 |
| miR-210                    | HCC        | QGY-7703, HepG2, SK-Hep-1, and Huh-7 | Tumor           | HUVEC       | Inhibition of SMAD4 and STAT6 expression | Lin et al. 106 |
| miR-210                    | BC         | 4T1             | Tumor           | EC          | Upregulation of VEGF | Jung et al. 52 |
| miR-210                    | LC         | NIH/3T3         | Tumor           | CAF         | JAK2/STAT3 pathway | Fan et al. 107 |

(Continued on next page)
thus, circRNAs are more stable than linear RNA. Research investigating the biological functions of circRNAs in recent years has shown that they play an important role in tumorigenesis, reproduction, metastasis, and invasion, especially in tumor angiogenesis. Some studies noted that abnormal expression of circRNAs is an important regulator of angiogenesis by regulating various cancer markers. This process may be determined by exosomes because they play a key role in regulating the cross talk between normal cells and cancer cells in the TME. Recent studies have shown that circRNA-100338 is overexpressed in exosomes secreted by HCC cells. Exosome-derived circRNA-100338 binds 14 RNA-binding proteins in human umbilical vein endothelial cells (HUVECs), especially NOVA2, and is thought to regulate vascular development and lumen formation, thereby stimulating angiogenesis. Thus, circRNAs play a key role in maintaining and promoting tumor progression.

| Exosome-derived ncRNA type | Tumor type | Study cell line | Source cell line | Target cell | Regulatory mechanism | Reference |
|---------------------------|------------|----------------|-----------------|-------------|----------------------|-----------|
| miR-221-3p                | CSCC       | SiHa and C33a  | Tumor           | EC          | Downregulation of THBS2 | Wu et al. 106 |
| miR-340                   | MM         | RPMI8226       | BMSC            | EC          | HGF/c-MET pathway     | Umezlu et al. 107 |
| miR-376b-3p               | Glioma     | U87MG          | Serum           | Not mentioned | Targets HOXD10        | Jiang et al. 110 |
| miR-451a                  | HCC        | SMMC-7721      | Tumor           | HUVEC       | Inhibition of LPIN1 expression | Zhao et al. 111 |
| miR-494                   | NSCLC      | A549, H1299, and HCC827 | Tumor | EC | Akt/eNOS pathway | Mao et al. 87 |
| miR-501-3p                | PDAC       | PANC-1 and BsPC-3 | TAM | HMEC | Downregulation of TGF-β3 | Yin et al. 87 |
| miR-619-5p                | NSCLC      | A549, H460, and BEAS-2B | Tumor | HUVEC | Inhibition of RCAN1.4 | Kim et al. 112 |
| linc-CCAT2                | Glioma     | U87MG          | Tumor           | HUVEC       | Upregulation of VEGFA and TGF-β | Lang et al. 113 |
| Inc-CCAT2                 | NPC        | CNE2 and NP69  | Tumor           | HUVEC       | Not mentioned         | Zhou et al. 114 |
| linc-POU3F3               | Glioma     | A172           | Tumor           | HBMVEC      | Upregulation of bFGF, bFGFR, VEGF and angiogenin | Lang et al. 115 |
| IncRNA GAS5               | LC         | A549, H1299, and 95D | Tumor | HUVEC | PTEN-P38K/Akt pathway | Cheng et al. 116 |
| IncRNA H19                | HCC        | Hah7           | SC              | HUVEC       | Upregulation of VEGFA | Conigliaro et al. 88 |
| IncRNA HOTAIR             | Glioma     | A172           | Tumor           | HBMVEC      | Upregulation of VEGFA | Ma et al. 117 |
| IncRNA MALAT1             | EOC        | SKOV3.ip1 and HO8910.PM | Tumor | HUVEC | Upregulation of certain angiogenesis-related genes | Qiu et al. 118 |
| IncRNA TUG1               | CC         | HeLa and CaSki | Tumor           | HUVEC       | Inhibits caspase-3 activity and impacts apoptosis-related proteins | Lei et al. 119 |
| circRNA-100338            | HCC        | Hep3B and MHCC97H | Tumor | HUVEC | May upregulate NOVA2 | Yang et al. 120 |
| circRNA- CMTM3            | HCC        | Huh7, Hep3B, HCCLM3, SK-Hep-1, HCCLM7, and THLE-2 | Tumor | HUVEC | Sponges miR-3169-5p and disinhbits SOX9 | Hu et al. 121 |
| HGF siRNA                 | GC         | HEK293T        | GC              | HEK293T     | Inhibition of HGF and VEGF expression | Zhang et al. 122 |

HUVEC, human umbilical vein endothelial cell; MM, multiple myeloma; NPC, nasopharyngeal carcinoma; MDK, midkine; BC, breast cancer; MSC, mesenchymal stem cell; CML, chronic myelogenous leukemia; RhoB, ras homolog family member B; LC, lung cancer; HNSCC, human head and neck squamous cell carcinoma; CRC, colorectal cancer; HCC, hepatocellular carcinoma; ITAC, intestinal-type sinonasal adenocarcinoma; GC, gastric cancer; FH1-1, factor-inhibiting HIF-1; EOC, epithelial ovarian cancer; LARC, locally advanced rectal cancer; LAC, lung adenocarcinoma; PTPN, phosphatase and tensin homolog; TGF-βRI, transforming growth factor-β receptor 1; HMEC, human microvascular endothelial cell; OS, osteosarcoma; BL, Burkitt's lymphoma; ARPE-19, retinal pigment epithelial cells-19; OC, ovarian cancer; EFNA3, ephrin A3; CAF, cancer-associated fibroblast; CSCC, cervical squamous cell carcinoma; THBS2, thrombospondin-2; BMSC, bone marrow stromal cell; NSCLC, non-small-cell lung cancer; PDAC, pancreatic ductal adenocarcinoma; TAM, tumor-associated macrophage; RAC1, a cancer cell; HBMVEC, human brain microvascular endothelial cell; HBMVEC, human brain microvascular endothelial cell; OC, ovarian cancer; HCC, hepatocellular carcinoma; HGF, hepatocyte growth factor.
DUALITY OF EXOSOME-DERIVED ncRNAs IN TUMOR ANGIOGENESIS

Tumor angiogenesis is a process involving the pathological proliferation of new capillaries in the pre-existing vascular system. This process is controlled by various growth factors and different signal transduction pathways and depends on the balance of proangiogenic and antiangiogenic factors. Exosome-derived ncRNAs play an important role in mediating intercellular communication. Numerous studies have found that ncRNAs play a dually important role in the process of destroying the balance of angiogenesis (Table 2).

In recent years, studies have indicated that exosome-derived ncRNAs directly regulate the expression of the VEGF gene, increase vascular permeability and density, accelerate tumor angiogenesis, and promote tumor growth and metastasis. For example, the IncRNAs HOTAIR and VEGFA have been found to be overexpressed and coexpressed in gliomas. Further studies showed that the IncRNA HOTAIR is transported into ECs through exosomes and then directly targets the VEGFA promoter to promote VEGFA transcription, thereby accelerating the proliferation and migration of ECs to stimulate angiogenesis. Similarly, studies reported that overexpressed miR-155 promotes angiogenesis by transferring exosomes to retinal epithelial pigment cells and upregulating the expression of VEGFA.

In contrast to the angiogenic effect mentioned above, exosome-derived ncRNAs also play an important antiangiogenic role due to their anticancer activity. Some studies showed that miR-23b and miR-320b were overexpressed in exosomes in breast cancer MCF7 cells after treatment with docosahexaenoic acid (DHA). After acting on ECs, the expression of angiogenic target genes (PLAU, AMOTL1, NRP1, and ETS2) is reduced, and endothelial cell tube formation is inhibited. In addition, exosomes secreted by nasopharyngeal carcinoma cells are rich in miR-9, which directly targets the angiogenic gene MDK in ECs and interferes with PDK1/Akt, a proangiogenic pathway. Further studies showed that the expression of exosome-derived miR-9 is negatively correlated with the microvessel density.

Interestingly, the same ncRNAs were found to play dual roles in tumor angiogenesis. In recent years, miR-21 has attracted widespread attention due to its important role in regulating tumor angiogenesis and is enriched in exosomes secreted by various cells. For example, overexpressed exosome-derived miR-21 promotes the formation of the tubular structure of HUVECs by upregulating the level of VEGF in human bronchial ECs. In addition, glioma stem cells promote angiogenesis by overexpressing exosome-derived miR-21 to induce an increase in VEGF in ECs. However, in leukemia, overexpressed exosome-derived miR-21 plays an antiangiogenic role by targeting ECs to inhibit RhoB gene expression and then negatively regulate EC movement.

The regulation of angiogenesis by different exosome-derived ncRNAs in the same tumor also displays duality. For example, in breast cancer, in animal experiments, MSC exosome-derived miR-16 acts directly on breast cancer cells while reducing the expression of VEGF, showing antitumour angiogenesis and inhibiting tumor growth. In addition, exosomes secreted by breast cancer cells under hypoxia contain a large amount of miR-210. miR-210 is overexpressed in ECs and downregulates the ephrin-A3 and PTP1B genes, which inhibit vascular remodeling. Therefore, exosome-derived miR-210 promotes angiogenesis. These findings reveal the potential role of exosome-derived ncRNAs in breast cancer and provide novel insight into breast cancer prognosis and therapeutic strategies.

ROLES OF EXOSOME-DERIVED ncRNAs IN THE REGULATION OF ANGIOGENESIS IN DIFFERENT CANCERS

Angiogenesis plays a critical role in the occurrence, development and even prognosis of tumors. Abnormal angiogenesis has been confirmed to be related to human cancer. In fact, tumor angiogenesis mostly begins with the release of molecules from tumor cells that signal to promote vascular growth and lead to a local imbalance between stimulating and inhibiting angiogenesis. It has been confirmed that exosomes can participate in the regulation of tumor angiogenesis through ncRNAs to promote tumor progression. Numerous studies have suggested that abnormal ncRNA expression in multiple organs in different human systems activates angiogenic signal pathways in ECs to stimulate angiogenesis, leading to the occurrence and progression of cancer. The function and potential application of exosome-derived ncRNAs in regulating angiogenesis in cancer are worthy of affirmation and may be gradually proven in future studies.

Digestive system
Liver cancer
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. Previous studies have shown that the expression of miR-451a is downregulated in many human cancers, which is related to tumor suppression. Recent studies showed that exosome-derived miR-451a, as a tumor suppressor, specifically targets LPIN1 to induce apoptosis in HCC cells and HUVECs, thereby inhibiting angiogenesis and, thus, the occurrence of HCC. H19 is closely related to the occurrence of liver cancer, liver metastasis, and angiogenesis. In another study, CD90+ hepatoma cells were shown to be rich in IncRNAH19, which was transferred to ECs through exosome release, promoting an angiogenic phenotype and cell-to-cell adhesion, stimulating angiogenesis, and promoting cell-cell interactions. These studies indicate the important role of exosome-derived ncRNAs in HCC and shed light on the pathogenesis of HCC, providing targets for the development of future therapy.

Gastric cancer
C-MYB, a transcription factor, plays an important role in angiogenesis. miR-130a is overexpressed in exosomes from gastric cancer (GC) cells and acts as a driver of angiogenesis by downregulating the C-MYB protein by targeting 3′-UTR C-MYB mRNA in HUVECs, thereby promoting angiogenesis and tumor growth. HGF siRNA packaged in exosomes could be transported to GC cells to...
significantly downregulate the expression of HGF (which promotes the growth of tumor cells and vascular cells), thereby inhibiting angiogenesis and cancer cell and vascular cell proliferation and migration.\textsuperscript{122} Therefore, antixosome-derived ncRNAs might be a novel antiangiogenic therapeutic strategy for gastric cancer.

**Colorectal cancer**

In cancer cells from patients with colorectal cancer (CRC) with tumor metastasis, miR-25-3p is abundant and is transferred to ECs and internalized by exosomes. Targeted KLF2 and KLF4 promote vascular permeability and angiogenesis by upregulating the expression of VEGFR2, ZO-1, occludin and claudin5. Animal experiments confirmed that miR-25-3p enhanced the metastasis of CRC cells to the liver and lung by inducing vascular leakage.\textsuperscript{95} Therefore, exosome-derived miR-25-3p is a novel biomarker with promising applications in the clinical diagnosis of CRC.

**Pancreatic cancer**

The most common type of pancreatic cancer is PDAC. Exosome-derived miR-501-3p in M2 macrophages is overexpressed under

### Table 2. Duality of exosome-derived ncRNAs in tumor angiogenesis

| Function          | Exosome-derived ncRNA type | Tumor type | Dysregulation | Reference          |
|-------------------|---------------------------|------------|---------------|--------------------|
| **Proangiogenesis** | miR-9                     | Melanoma   | Up            | Zhuang et al.\textsuperscript{35} |
|                   | miR-21                    | LC         | Up            | Liu et al.\textsuperscript{84}   |
|                   | miR-23a                   | NPC        | Up            | Bao et al.\textsuperscript{93}    |
|                   | miR-25-3p                 | CRC        | Up            | Zeng et al.\textsuperscript{85}   |
|                   | miR-32-5p                 | HCC        | Up            | Fu et al.\textsuperscript{77}     |
|                   | miR-92a                   | CML        | Up            | Umezui et al.\textsuperscript{96} |
|                   | miR-130a                  | GC         | Up            | Yang et al.\textsuperscript{82}   |
|                   | miR-135b                  | MM         | Up            | Umezui et al.\textsuperscript{86} |
|                   | microR-141-3p             | EOC        | Up            | Masouni-Delghii et al.\textsuperscript{77} |
|                   | miR-142-3p                | LAC        | Up            | Lawson et al.\textsuperscript{142} |
|                   | miR-148a                  | OS         | Up            | Raimondi et al.\textsuperscript{132} |
|                   | miR-21-5p                 | BL         | Up            | Yoon et al.\textsuperscript{132}  |
|                   | miR-155                   | Melanoma   | Up            | Zhou et al.\textsuperscript{104}  |
|                   | miR-155-5p                | OC         | Up            | He et al.\textsuperscript{105}    |
|                   | miR-205                   | CML        | Up            | Tadokoro et al.\textsuperscript{7} |
|                   | miR-221-3p                | CSCC       | Up            | Wu et al.\textsuperscript{108}    |
|                   | miR-23b                   | NSCLC      | Up            | Mao et al.\textsuperscript{97}    |
|                   | miR-320b                  | PDAC       | Up            | Yin et al.\textsuperscript{97}    |
|                   | miR-494                   | NSCLC      | Up            | Jin et al.\textsuperscript{112}   |
|                   | miR-501-3p                | NPC        | Up            | Zhou et al.\textsuperscript{114}  |
|                   | linc-CCAT2                | Glioma     | Up            | Lang et al.\textsuperscript{114}  |
|                   | linc-POUSF3               | Glioma     | Up            | Ma et al.\textsuperscript{117}    |
|                   | lncRNA HOTAIR             | Glioma     | Up            | Qiu et al.\textsuperscript{118}   |
|                   | lncRNA MALAT1             | EOC        | Up            | Lei et al.\textsuperscript{139}   |
|                   | lncRNA TUG1               | CC         | Up            | Hu et al.\textsuperscript{124}    |
|                   | circRNA-CMTM3             | HCC        | Up            |                       |
|                   | miR-9                     | NPC        | Down          | Lu et al.\textsuperscript{92}     |
|                   | miR-16                    | BC         | Down          | Lee et al.\textsuperscript{92}    |
|                   | miR-21                    | CML        | Down          | Taverna et al.\textsuperscript{99}|
|                   | miR-23b                   | BC         | Down          | Hannafon et al.\textsuperscript{54} |
|                   | miR-320b                  | BC         | Down          | Tomasetti et al.\textsuperscript{27} |
|                   | miR-126                   | ITAC       | Down          | Umezui et al.\textsuperscript{20} |
|                   | miR-340                   | MM         | Down          | Jiang et al.\textsuperscript{130} |
|                   | miR-376b-3p               | Glioma     | Down          | Zhao et al.\textsuperscript{130}  |
|                   | miR-451a                  | HCC        | Down          | Cheng et al.\textsuperscript{130} |
hypoxia and inhibits the tumor suppressor TGFBR3 gene to promote PDAC cell migration, invasion, and angiogenesis by activating the TGF-β signaling pathway. Therefore, exosome-derived miR-501-3p could be a potential therapeutic pathway in PDAC.

Respiratory system
Lung cancer
Lung cancer (LC) is the leading cause of cancer death worldwide. Studies have confirmed that exosomes in lung adenocarcinoma cells accumulate a large amount of miR-142-3p, which is targeted to inhibit TGF-β receptor 1 and promote angiogenesis when transferred to ECs. In addition, promoting the phenotype of cancer-related fibroblasts in lung fibroblasts is not related to TGF-β signaling. Exosomes of human bronchial epithelial (HBE) cells transformed by cigarette smoke extract (CSE) were rich in miR-21 and transferred to normal HBE cells through exosomes, resulting in STAT3 activation and the upregulation of VEGF expression in HBE cells, which, in turn, led to angiogenesis in HUVECs and the malignant transformation of HBE cells, indicating the critical regulatory role of exosomes in LC angiogenesis.

Nasopharyngeal carcinoma
Exosome-derived miR-9 from nasopharyngeal carcinoma (NPC) cells play a special role in the cross talk between tumors and the microenvironment. miR-9 directly inhibits the target gene MDK in ECs, which is positively related to microvessel density and prevents the formation and migration of blood vessels through the PDK/Akt signaling pathway. In another study, researchers established an animal model to confirm that miR-23a in NPC is highly related to the microvessel density, and the overexpression of exosome-derived miR-23a in NPC directly targets specific gene antigens to promote angiogenesis in vivo and in vitro. These findings suggest that miR-9 or sequence-specific inhibitors targeting miR-23a may serve as novel therapeutic avenues for NPC.

Sinonasal cancer
A study reported that intestinal-type sinonasal adenocarcinomas (ITACs), which account for approximately 8%–25% of SNCs, are malignant epithelial tumors related to sawdust contact. The ectopic expression of exosome-derived miR-126 from HUVECs inhibits malignant nasal septum carcinoma cell growth and affects cell metabolism, significantly reducing VEGF gene expression associated with reduced colony formation and inhibiting cell migration and proliferation. However, the correlation between miR-126 and HUVECs and the specific mechanism require further experimental studies.

Blood system
Multiple myeloma
Some studies have shown that numerous proliferating multiple myeloma (MM) cells lead to hypoxia, and miR-135b in the exosomes of MM cells is significantly upregulated. After being transported to ECs, miR-135b inhibits (FIH-1 and activates the HIF-FIH signaling pathway to enhance angiogenesis under hypoxic conditions. As a consequence, miR-135b may be a target for controlling MM angiogenesis.

Burkitt’s lymphoma
Exosomes of human EBV-positive Burkitt’s lymphoma (BL) cells (Raji) contain a large amount of miR-155, and Raji transfers overexpressed miR-155 into retinal epithelial pigment cells (ARPE-19) and induces angiogenesis by enhancing VEGFα transcription and translation, providing a new method for monitoring the transfer of BL.

Chronic myeloid leukemia
Some studies have shown that miR-210 in the exosomes of the human leukemia cell line K562 were significantly increased under hypoxia and promoted the angiogenic activity of ECs by downregulating the receptor tyrosine kinase ligand ephrin-A3, thereby promoting the tube formation of HUVECs. In addition, based on fluorescence labeling, the exosomes released by K562 cells contain a large amount of miR-92a, which specifically inhibits the expression of the integrin z5 gene in HUVECs and promotes angiogenesis. This finding may suggest that exosome-derived ncRNAs have the capacity to predict prognosis and guide the use of drugs in the treatment of chronic myeloid leukemia CML.

Reproductive system
Epithelial ovarian cancer
In cancer cells from patients with epithelial ovarian cancer (EOC) with tumor metastasis, the IncRNA MALAT1, which is abundant in exosomes, is transferred to HUVECs through exosomes and internalized to promote angiogenesis. By use of a MALAT1 gene knockout experiment, this proangiogenic activity was greatly weakened. With further understanding of the relationship between ncRNAs and angiogenesis, the IncRNA MALAT1 may provide insight into personalized and accurate treatment for EOC.

Cervical cancer
A recent study found that the IncRNA TUG1 has a significant upregulation effect in serum exosomes from patients with cervical cancer (CC), and for the first time, it was confirmed that CC cells can transfer the IncRNA TUG1 to HUVECs through exosomes by inhibiting caspase-3 activity and affecting apoptosis-related proteins to promote tumor angiogenesis and HUVEC proliferation. Therefore, the IncRNA TUG1 may be used to evaluate the prognosis of patients with CC.

Endocrine system
Breast cancer
Exosomes secreted by hypoxic breast cancer (BC) cells mediate the entry of miR-210 into ECs to inhibit the expression of the ephrin-A3 and PTP1B genes, which increase VEGF and promote VEGF-mediated EC recruitment, thereby promoting the formation of new capillaries and tubular structures. In addition, exosome-derived miR-100 from MSCs induces the decreased expression of VEGF and inhibits angiogenesis and tumor growth by regulating the mammalian target of rapamycin (mTOR)/HIF-1α signal transduction pathway.
transduction axis in BC cells; however, exosome-derived miR-100 from MSCs downregulates the metastasis of BC cells and downregulates VEGF in a time-dependent manner. These studies provide a new perspective regarding intervention strategies to prevent the carcinogenesis of BC.

Other cancers

Glioma
Glioma cells are rich in linc-CCAT2, which is absorbed by ECs through exosome release. Its overexpression activates VEGF and TGF-β, promotes angiogenesis and the expression of Bcl-2, and inhibits the expression of Bax and caspase-3, thereby reducing apoptosis. Another study confirmed that exosomes derived from glioma stem cells promote the angiogenesis of ECs by carrying miR-21 and VEGF to ECs and then stimulating the miR-21/VEGF/VEGFR2 signaling pathway. These findings suggest that exosome-derived ncRNAs are of great interest in glioma.

Human head and neck squamous cell carcinoma
Snail is a recruitment transcription factor that promotes TAM activation, which induces the epithelial-mesenchymal transformation and leads to tumor progression and metastasis. The exosomes of human head and neck squamous cell carcinoma (HNSCC) cells are rich in miR-21, which is directly activated and expressed by Snail and captured by CD14+ human monocytes, thereby increasing the polarized expression of M2 labeled by TAMs, promoting angiogenesis, increasing tumor invasion, and accelerating tumor progression. These exosome-derived ncRNAs may serve as candidate biomarkers of tumor progression.

Melanoma
miR-9 derived from melanoma exosomes effectively promotes tumor angiogenesis by downregulating the level of suppressor of cytokine signal 5 (SOCS-5) and activating JAK-STAT as a carcinogenic signaling pathway. These findings may provide insight into the clinical treatment of melanoma.

POTENTIAL CLINICAL APPLICATION OF EXOSOME-DERIVED ncRNAs

In recent years, exosome-derived ncRNAs have been shown to have great potential in antitumor clinical applications due to their important role in the key steps of tumor angiogenesis and may be used to identify tumors and even change tumor progression. Exosomes have similar proteins and lipids as their parent cells on the surface, which not only successfully transfer the ncRNAs that they carry to recipient cells but also aid in evading autoimmunity. In addition, exosomes and the ncRNAs they carry are highly stable and exhibit strong biological activity; thus, they play an important role. Therefore, exosome-derived ncRNAs are considered a new tool that could improve cancer diagnosis, treatment, and prognosis.

Tumor biomarkers
The application of biomarkers is of great value in the diagnosis and prognosis of tumors, and the search for reliable biomarkers is significant for the early treatment of tumors. Numerous exosome-derived ncRNAs that affect tumor angiogenesis are overexpressed in patients with specific tumors, and their content in bodily fluids is high and stable; thus, they are easily evaluated in clinical practice. Therefore, exosome-derived ncRNAs are used as potential biomarkers for the detection of different malignant tumors (Figure 3).

As a diagnostic indicator, miR-23a is higher in serum exosomes from patients with LC, especially in patients with hypoxic LC, than in normal controls. In vitro experiments have shown that the expression level of these exosome-derived miRNAs in hypoxic tumor cell lines is higher than that in normoxic tumor cell lines. A positive correlation exists between the level of exosome-derived miR-23a and angiogenic activity; thus, exosome-derived miR-23a is used as a biomarker for the personalized diagnosis of LC. In addition, exosome-derived miR-21 reportedly promotes angiogenesis in HNCC by participating in the mechanism of EMT-mediated M2 polarization and is listed as a candidate biomarker for the diagnosis of tumor progression.

Exosome-derived ncRNAs are also used as prognostic indicators. A study found that circRNA-100338 is significantly increased in serum exosomes from patients with lung metastasis after HCC surgery, and these patients significantly differ from healthy patients, demonstrating that patient prognosis is poor. The sensitivity and specificity of exosome-derived circRNA-100338 are better than those of α-fetoprotein (AFP), which is a traditional marker; therefore, exosome-derived circRNA-100338 is used as a potential prognostic index.

Generally, exosome-derived ncRNAs are expected to be used as new noninvasive biomarkers in the diagnosis and prognosis of cancer. However, the small size of the experimental sample was not ideal, and the credibility of a single molecule is limited. The potential of exosome-derived ncRNAs as cancer biomarkers must be further verified in more patients with cancer.

Therapeutic targets

Humans never stop exploring new ways to treat cancer. Aggressive malignant tumors must be powered by pathological angiogenesis. Clinical data have shown that blocking angiogenesis delays tumor progression. Studies have shown that exosome-derived ncRNAs regulate tumor angiogenesis. Therefore, with the in-depth understanding of exosome-derived ncRNAs, the use of their precise targeting to inhibit tumor-angiogenesis-related cells or molecules has become a new means of cancer treatment.

siRNAs are short (21–23 nucleotides in length), double-stranded, noncoding RNAs with an mRNA sequence and an antisense active strand. siRNAs mediate RNA interference (RNAi) to specifically knock out the expression of a target gene. The chemical synthesis of siRNA for clinical use is considered a promising therapeutic tool that acts on sequence-specific endonuclease cleavage of mRNA and leads to specific gene silencing. However, because siRNAs easily decompose in vivo, they are generally loaded into exosomes and transported to target cells. Exosomes transmit siRNA to target cells...
and interfere with the expression of angiogenesis-related molecules by gene silencing, thereby playing an important role in affecting tumor angiogenesis. Exosome-derived HGF siRNA reportedly inhibits the growth and angiogenesis of gastric cancer. HGF is a tumor marker that upregulates VEGF. Exosome-derived HGF siRNA acts on GC cells and inhibits the proliferation and migration of cancer cells and vascular cells by inducing the HGF/c-Met signal transduction pathway to downregulate VEGF expression. Although the therapeutic effect on exosome-derived siRNA cancer is not yet mature, this method has produced surprising results. Exosome-derived siRNAs may serve as key targets for tumor treatment and open up new directions for future research concerning tumour-targeted therapy.

In addition, some drugs stimulate an increase or decrease in ncRNAs in tumor exosomes to regulate specific genes or pathways to affect tumor angiogenesis. For example, CML cells treated with curcumin overexpress miR-21 in their exosomes, and then, miR-21 is internalized in ECs and directly downregulates the expression of RhoB, which reduces the angiogenesis ability of HUVECs. Therefore, research investigating the targets of exosome-derived ncRNAs as a breakthrough could provide new insight into targeted cancer therapy in the future, and research concerning these topics could become a potential way to prevent and control cancer metastasis.

CONCLUSION AND FUTURE PERSPECTIVES

Some of the latest research results concerning exosomes and ncRNAs are inspiring. For example, the commonly used exosomal biomarkers differ and do not show universal utility in different cell types. In addition, specific oncogenes promote the release of exosomes and change secreted ncRNAs, such as miRNAs, to reduce the biomass of cancer cells. Recent discoveries related to various ncRNAs that promote the disturbance of a tumor’s internal environment have generated discussions regarding the related mechanisms. Therefore, the early detection of tumor occurrence and progression by evaluating specific exosome-derived ncRNA biomarkers has become a new hot topic in recent years.

In summary, exosome-derived ncRNAs affect tumor progression by regulating tumor angiogenesis. With the in-depth exploration of high-throughput sequencing technology and bioinformatics analyses in the medical field, an increasing number of exosome-derived ncRNAs from different types of cells will be identified and detected, which could further help us understand the mechanism promoting or inhibiting tumor angiogenesis. Therefore, the development of drugs targeting exosome-derived ncRNAs may represent a new method for the treatment of tumors. However, the role of exosome-derived ncRNAs in angiogenesis is a new field of cancer research, and only a few have a definite function or clinical application. We are currently limited to hypothesizing most functions of exosome-derived ncRNAs, and thus, we still need to explore the detailed mechanism. Exosome-derived ncRNAs show great potential as tumor markers and tumor treatment, but more studies are needed before advanced treatments for cancer are successfully developed and widely used in the clinical field. For example, the challenge of low exosome production needs to be solved in advance, and several strategies, such as serum starvation, have been explored to maximize the harvest. Because of its ability to promote autophagy and apoptosis, serum starvation has become a method that can promote the degree and content of pure exosomes and ensure the biological activity of exosomes, but this method also has the disadvantages of low efficiency and long time consumption. In addition, how to isolate and purify exosomes while retaining only ncRNAs with antitumor angiogenesis properties is a key problem to be solved. We believe that the use of exosome-derived ncRNAs as noninvasive fluid biopsy and noninvasive biomarkers for the early diagnosis of tumors, treatment of cancer, and prognosis prediction is a challenging but interesting task for the future that needs further exploration by researchers and clinicians.

ACKNOWLEDGMENTS

This study was supported by the National Natural Science Foundation of China (81972663 and 82173055), the National Natural Science Foundation of Henan Province (212300410074), the Key Scientific Research Projects of Institutions of Higher Education in Henan Province (19A310024), the Medical Scientific and Technological Research Project of Henan Province (201702027), the Youth Innovation Fund Project of the First Affiliated Hospital of Zhengzhou University (YNQN2017035), the China Postdoctoral Science Foundation (2019T120648), the National Natural Science Foundation of Henan
Province (182300410342) and the Health Commission Technology Talents Overseas Training Project of Henan Province (2018140).

AUTHOR CONTRIBUTIONS
K.Y. wrote the manuscript and created the figures. Z.S. and W.Y. provided direction and guidance throughout the preparation of this manuscript. B.Q. and B.S. reviewed and made significant direction and guidance throughout the preparation of this manuscript. Q.Z., S.H., and G.W. collected and prepared the related papers. All authors read and approved the final manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
1. Pagano, E., Elias, J.E., Schneditz, G., Saveljeva, S., Holland, L.M., Borrelli, F., Karlsen, T.H., Kaser, A., and Kanaeder, N.C. (2021). Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment. Gut.
2. Kikuchi, S., Yoshioka, Y., Prieto-Vila, M., and Ochiya, T. (2019). Involvement of extracellular vesicles in vascular-related functions in cancer progression and metastasis. Int. J. Mol. Sci. 20, 2584.
3. Théry, C., Regnault, A., Garin, J., Wollers, J., Zitvogel, L., Ricciardi-Castagnoli, P., Raposo, G., and Amigorena, S. (1999). Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J. Cell Biol. 147, 599–610.
4. Hendrix, A., Maynard, D., Pauwels, P., Braems, G., Denys, H., Van den Broecke, R., Lieberman, J. (2014). miR-200-containing extracellular vesicles promote breast cancer metastasis. J. Clin. Invest. 123, 1542–1555.
5. Le, M.T.N., Hamar, P., Guo, C., Basar, E., Perdigão-Henriques, R., Balaj, L., and Lieberman, J. (2014). miR-200-containing extracellular vesicles promote breast cancer metastasis. J. Clin. Invest. 124, 5109–5128.
6. Dupont, C., Jullien, M., Dromard, F., Haidar, W., and Thibault, S. (2014). Extracellular vesicles mediate squamous cell carcinomas. J. Extracell Vesicles 3, 24570.
7. Sun, T., Kallioni, B., Lye, G., Xia, S., and Gao, W. (2015). Role of exosomal noncoding RNAs in lung carcinogenesis. Biomed. Res. Int. 2015, 125807.
8. Chen, L.-L., and Yang, L. (2015). Regulation of circRNA biogenesis. RNA Biol. 12, 381–388.
9. Dijkstra, S., Davis, C.A., Merkle, A., Dobin, A., Lassmann, T., Mortazavi, A., Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012). Landscape of transcription in human cells. Nature 489, 101–108.
10. Bullock, M.D., Silva, A.M., Kanelidou-Unaldi, P., Filant, J., Rashed, M.H., Sood, A.K., Lopez-Berestein, G., and Calin, G.A. (2015). Exosomal non-coding RNAs: diagnostic, prognostic and therapeutic applications in cancer. Non-coding RNA J., 53–68.
11. Kosaka, N., Iuchi, H., Hagiwara, K., Yoshioka, Y., Takeshita, F., and Ochiya, T. (2013). Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J. Biol. Chem. 288, 10849–10859.
12. Johnston, R.M., Adam, M., Hammond, J.R., Orr, L., and Turbide, C. (1987). Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem. 262, 9412–9420.
dependent activation of vascular cells during tumor development. Proc. Natl. Acad. Sci. U S A. 110, 7312–7317.
35. Zhuang, G., Wu, X., Jiang, Z., Kasman, I., Yao, J., Guan, Y., Oeh, I., Modrusan, Z., Bais, C., Sampath, D., et al. (2012). Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 31, 3513–3523.
36. Gajos-Michniewicz, A., Ducheck, M., and Czyz, M. (2014). miRNA in melanoma-derived exosomes. Cancer Lett. 347, 29–37.
37. Esteller, M. (2011). Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861–874.
38. Taft, R.J., Pang, K.C., Mercer, T.R., Dinger, M., and Mattick, J.S. (2010). Non-coding RNAs: regulators of disease. J. Pathol. 220, 126–139.
39. Stein, L.D. (2004). Human genome: end of the beginning. Nature 431, 915–916.
40. Mao, L., Li, X., Gong, S., Yuan, H., Jiang, Y., Huang, W., Sun, X., and Dang, X. (2018). Serum exosomes contain ECRG4 mRNA that suppresses tumor growth via inhibition of genes involved in inflammation, cell proliferation, and angiogenesis. Cancer Gene Ther. 25, 248–259.
41. Greening, D.W., Gopal, S.K., Xu, R., Simpson, R.I., and Chen, W. (2015). Exosomes and their roles in immune regulation and cancer. Semin. Cell Dev. Biol. 40, 72–81.
42. Richards, K.E., Zelenik, A.E., Fishel, M.L., Wu, J., Littlepage, L.E., and Hill, R. (2017). Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene 36, 1770–1778.
43. Salido-Guardarrama, I., Romero-Cordoba, S., Peralta-Zaragoza, O., Hidalgo-Miranda, A., and Rodriguez-Dorantes, M. (2014). MicroRNAs transported by exosomes in body fluids as mediators of intercellular communication in cancer. Onco Targets Ther. 7, 1327–1338.
44. Liu, Y., Luo, F., Wang, B., Li, H., Xu, Y., Liu, X., Shi, L., Lu, X., Xu, W., Lu, L., et al. (2016). STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells. Cancer Lett. 370, 125–135.
45. Feitelson, M.A., Alrumeanyana, A., Kulathinal, R.J., Blain, S.W., Holcombe, R.F., Mahajna, J., Marino, M., Martinez-Chantar, M.L., Nawroth, R., Sanchez-Garcia, L., et al. (2015). Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin. Cancer Biol. 35, S25–S54.
46. Jung, K.O., Youn, H., Lee, C.-H., Kang, K.W., and Chung, J.-K. (2017). Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells. Oncotarget 8, 9899–9910.
47. Kogure, T., Lin, W.-L., Yan, I.K., Braconi, C., and Patel, T. (2011). Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 53, 1237–1248.
48. Gao, T., Liu, X., He, B., Nie, Z., Zhu, C., Zhang, P., and Wang, S. (2018). Exosomal lncRNA 91H is associated with poor development in colorectal cancer by modulating HNRNPK expression. Cancer Cell Int. 18, 11.
49. Sun, Z., Yang, S., Zhou, Q., Wang, G., Song, J., Li, Z., Zhang, Z., Xu, J., Xia, K., Chang, Y., et al. (2018). Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment. Mol. Cancer 17, 82.
50. Vielle, C., and Larivière, B. (2017). Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis 20, 409–426.
51. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186.
52. Mehen, P., and Puiseux, A. (2006). Metastasis: a question of life or death. Nat. Rev. Cancer 6, 449–458.
53. Ribeiro, M.F., Zhu, H., Millard, R.W., and Fan, G.-C. (2013). Exosomes function in pro- and anti-angiogenesis. Curr. Angiogene. 2, 54–59.
54. Bergers, G., and Benjamin, L.E. (2003). Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401–410.
55. Park, J.E., Tan, H.S., Datta, A., Lai, R.C., Zhang, H., Meng, W., Lim, S.K., and Sze, S.K. (2010). Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol. Cell Proteomics 9, 1085–1099.
contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 70, 1668–1678.

77. Fu, X., Liu, M., Qu, S., Ma, J., Zhang, Y., Shi, T., Wen, H., Yang, Y., Wang, S., Wang, J., et al. (2018). Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J. Exp. Clin. Cancer Res. 37, 52.

78. Capone, F., Guerrero, E., Colonna, G., Maio, P., Mangia, A., Castello, G., and Costantini, S. (2014). Cytokine profile evaluation in patients with hepatitis C virus infection. World J. Gastroenterol. 20, 9261–9269.

79. Li, N., Long, B., Han, W., Yuan, S., and Wang, K. (2017). microRNAs: important regulators of stem cells. Stem Cell Res. Ther. 8, 110.

80. Pakravan, K., Babashah, S., Sadeghzadeh, M., Mowla, S.J., Mosahebi-Mohammadi, M., Ataie, F., Dana, N., and Javan, M. (2017). MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells. Cell Oncol. (Dordr) 40, 457–470.

86. Henze, A.T., and Mazzone, M. (2016). The impact of hypoxia on tumor-associated macrophages. Nat. Rev. Cancer 16, 1038–1044.

88. Chen, X., Yang, F., Zhang, T., Wang, W., Xi, W., Li, Y., Zhang, D., Huo, Y., Zhang, J., et al. (2018). Exosome-derived miR-130a activates angiogenesis in gastric cancer by targeting C-MYB in vascular endothelial cells. Mol. Ther. 26, 2466–2475.

92. Sun, X., Ma, X., Wang, J., Zhao, Y., Wang, Y., Bihl, J.C., Chen, Y., and Jiang, C. (2020). microRNA-141-3p-containing small extracellular vesicles derived from epithelial ovarian cancer cells promote endothelial cell angiogenesis through activating the JAK/STAT3 and NF-κB signaling pathways. J. Cell Commun. signaling 14, 233–244.

93. Bao, L., You, B., Shi, S., Shan, Y., Zhang, Q., Yue, H., Zhang, J., Zhang, W., Shi, Y., et al. (2018). Exosome-derived miR-130a promotes angiogenesis and metastasis of human nasopharyngeal carcinoma cells. Carcinogenesis 39, 668–677.

95. Zeng, Z., Li, Y., Pan, Y., Lan, X., Song, F., Sun, J., Zhou, K., Liu, X., Ren, X., Wang, F., et al. (2018). Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat. Commun. 9, 5395.

96. Umezuzi, T., Ohyashiki, K., Kuroda, M., and Ohyashiki, J.H. (2013). Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene 32, 2747–2755.

97. Tomasetti, M., Re, M., Monaco, F., Gaetani, S., Rubini, C., Bertini, A., Pasquini, E., Bersaglieri, C., Bracci, M., Staffolani, S., et al. (2018). miR-126 in intestinal-type sinonasal adenocarcinomas: exosomal transfer of MiR-126 promotes anti-tumour responses. BMC Cancer 18, 896.

99. Lfr, I., Zhang, H., Ge, S., Ning, T., Bai, M., Li, J., Li, S., Sun, W., Deng, T., Zhang, L., et al. (2018). Exosome-derived miR-130a activates angiogenesis in gastric cancer by targeting C-MYB in vascular endothelial cells. Mol. Ther. 26, 2466–2475.

101. Lawson, J., Dickman, C., Towle, R., Jabalee, J., Javer, A., and Garnis, C. (2019). Exosomal miR-25-3p and miR-375 in metastatic progression of rectal cancer. Transl Oncol. 12, 1038–1044.

102. Meltzer, S., Bjornetto, T., Lyckander, L.G., Flatmark, K., Duedal, S., Samiippa, R., Johansen, C., Kaland, R., J., Redalen, K.R. (2019). Circulating exosomal miR-141-5p and miR-375 in metastatic progression of rectal cancer. Transl Oncol. 12, 1038–1044.

103. Raimondi, L., De Luca, A., Gallin, A., Costa, V., Russell, G., Cuscinio, N., Manno, M., Raccosta, S., Carina, V., Bellavia, D., et al. (2019). Osteosarcoma cell-derived exosomes affect tumor microenvironment by specific packaging of microRNAs. Cancerogenisis 41, 666–677.

104. Zhou, X., Yan, T., Huang, C., Xu, Z., Wang, L., Jiang, E., Wang, H., Chen, Y., Liu, K., Shao, Z., et al. (2018). Melanoma cell-secreted exosomal miR-155-5p induces proangiogenic switch of cancer-associated fibroblasts via SOCS1/JAK2/STAT3 signaling pathway. J. Exp. Clin. Cancer Res. 37, 242.

105. He, L., Zhu, W., Chen, Q., Yuan, Y., Kim, D., Hur, D.Y., Kim, B., and Kim, Y.S. (2019). Delivery of miR-155 to retinal pigment epithelial cells mediated by Burkitt’s lymphoma exosomes. Tumour Biol. 37, 313–321.

106. Lin, X.J., Fang, J.H., Yang, X.J., Zhang, C., Yuan, Y., Zheng, L., and Zhuang, S.M. (2018). Exosomal miR-9 inhibits angiogenesis by targeting mdm2 in breast cancer cells. Oncogene 37, 147.

107. Fan, J., Xu, G., Chang, Z., Zhu, L., and Yao, J. (2020). miR-210 transferred by lung adenocarcinoma cells promotes tumor growth and metastasis by targeting PECAM1 in angiogenic endothelial cells. Arch. Biochem. Biophys. 617, 896–902.

108. Wu, X.G., Zhou, C.F., Zhang, Y.M., Yan, R.M., Wei, W.F., Chen, X.J., Yi, H.Y., Liang, L.J., Fan, L.S., Liang, L., et al. (2019). Cancer-derived exosomal miR-221-3p promotes angiogenesis by targeting THBS2 in cervical squamous cell carcinoma. Angiogenesis 22, 397–410.

109. Umezuzi, T., Imanishi, S., Azuma, K., Kobayashi, C., Yoshizawa, S., Ohyashiki, K., and Ohyashiki, J.H. (2014). Exosomal miR-221-3p derived from gastric cancer cells promotes angiogenesis by targeting TUBB3 in vascular endothelial cells. Oncogene 33, 587–595.

110. Yoon, C., Kim, J., Park, G., Kim, S., Kim, D., Hur, D.Y., Kim, B., and Kim, Y.S. (2019). Exosomal miR-210 promotes angiogenesis by recruiting miR-210 to HUVEC cells. Cell Mol. Biol. Lett. 24, 2522–2523.
113. Lang, H.-L., Hu, G.-W., Zhang, B., Kuang, W., Chen, Y., Wu, L., and Xu, G.-H. (2017). Gioma cells enhance angiogenesis and inhibit endothelial cell apoptosis through the release of exosomes that contain long non-coding RNA CCAT2. Oncol. Rep. 38, 785–798.

114. Zhou, S.K., Gao, F., Zhong, Z.S., and Yao, H. (2020). Long non-coding RNA colon cancer associated transcript-2 from nasopharyngeal carcinoma-derived exosomes promotes angiogenesis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 55, 944–951.

115. Lang, H.L., Hu, G.W., Chen, Y., Liu, Y., Tu, W., Lu, Y.M., Wu, L., and Xu, G.H. (2017). Gioma cells promote angiogenesis through the release of exosomes containing long non-coding RNA POU3F3. Eur. Rev. Med. Pharmacol. Sci. 21, 959–972.

116. Cheng, Y., Dai, X., Yang, T., Zhang, N., Liu, Z., and Jiang, Y. (2019). Low non-coding RNA growth arrest-specific transcript 5 expression in the exosomes of lung cancer cells promotes tumor angiogenesis. J. Oncol. 2019, 2476175.

117. Ma, X., Li, Z., Li, T., Zhu, L., Li, Z., and Tian, N. (2017). Long non-coding RNA HOTAIR enhances angiogenesis by induction of VEGFA expression in glioma cells and transmission to endothelial cells via glioma cell-derived-extracellular vesicles. Am. J. translational Res. 9, 5012–5021.

118. Qiu, J.-J., Lin, X.-J., Tang, X.-Y., Zeng, T.-T., Lin, Y.-Y., and Hua, K.-Q. (2018). Exosomal metastasis-associated lung adenocarcinoma transcript 1 promotes angiogenesis and predicts poor prognosis in epithelial ovarian cancer. Int. J. Biol. Sci. 14, 1960–1973.

119. Lei, L., and Mou, Q. (2020). Exosomal taurine up-regulated 1 promotes angiogenesis and endothelial cell proliferation in cervical cancer. Cancer Biol. Ther. 21, 717–725.

120. Yang, M., Chen, J., Su, F., Yu, B., Su, F., Lin, L., Liu, Y., Huang, J.D., and Song, E. (2011). Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol. Cancer 10, 117.

121. Hu, K., Li, N.-F., Li, J.-R., Chen, Z.-G., Wang, J.-H., and Sheng, L.-Q. (2021). Exosome circMTM3 promotes angiogenesis and tumorigenesis of hepatocellular carcinoma through miR-3619-5p/SP0X9. Hepatol. Res. 51, 1139–1152.

122. Zhang, H., Wang, Y., Bai, M., Wang, J., Zhu, K., Liu, R., Ge, S., Li, J., Ning, T., Deng, T., et al. (2018). Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor siRNA. Cancer Sci. 109, 629–641.

123. Pontecorvi, G., Bellenghi, M., Puglisi, R., Care, A., and Mattia, G. (2020). Tumor-derived extracellular vesicles and microRNAs: functional roles, diagnostic, prognostic and therapeutic options. Cytokine Growth Factor Rev. 51, 75–83.

124. Gambari, R., Brogna, E., Spandidos, D.A., and Fabbrini, E. (2016). Targeting oncomiRnas and mimicking tumor suppressor microRNAs: new trends in the development of miRNA therapeutic strategies in oncology (Review). Int. J. Oncol. 49, 5–32.

125. St Laurent, G., Wahlestedt, C., and Kapranov, P. (2015). The Landscape of long non-coding RNA classification. Trends Genet. 31, 239–251.

126. Pang, Y., Liu, Z., Han, H., Wang, B., Li, W., Mao, C., and Liu, S. (2020). Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation. J. Hepatol. 73, 1155–1169.

127. Huang, J.-Z., Chen, M., Chen, D., Gao, X.-C., Zhu, S., Huang, H., Hu, M., Zhu, H., and Yan, G.-R. (2017). A peptide encoded by a putative lncRNA HOXB-AS3 suppresses colon cancer growth. Mol. Cell 68, 171–184.e6.

128. Wu, Y., Wang, Y., Wei, M., Han, X., Xu, T., and Cui, M. (2020). Advances in the study of exosomal IncRNAs in tumors and the selection of research methods. Biomed. Pharmacother. 123, 109716.

129. Zhang, Q., Wang, W., Zhou, Q., Chen, C., Yuan, W., Liu, J., Li, X., and Sun, Z. (2020). Roles of circRNAs in the tumour microenvironment. Mol. Cancer 19, 14.

130. Zhang, H., Zhu, L., Bai, M., Liu, Y., Zhan, Y., Deng, T., Yang, H., Sun, W., Wang, X., Zhu, K., et al. (2019). Exosomal circRNA derived from gastric tumor promotes white adipose browning by targeting the miR-133/PRDM16 pathway. Int. J. Cancer 144, 2501–2515.

131. Huang, X.Y., Huang, Z.L., Huang, J., Xu, B., Huang, X.Y., Xu, Y.H., Zhou, J., and Tang, Z.Y. (2020). Exosomal circRNA-100338 promotes hepatocellular carcinoma metastasis via enhancing invasiveness and angiogenesis. J. Exp. Clin. Cancer Res. 39, 20.

132. Carmelet, P., and Jain, R.K. (2011). Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417–427.

133. Cantelmo, A.R., Conradi, L.C., Brajic, A., Goveia, J., Kalucka, J., Pircher, A., Chaturvedi, P., Hol, J., Thiembont, P., Teuwen, L.-A., et al. (2016). Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, improves metastasis, and improves chemotherapy. Cancer Cell 30, 968–985.

134. Ronca, R., Benkheil, M., Mitola, S., Struyf, S., and Liekens, S. (2017). Tumor angiogenesis revisited: regulators and clinical implications. Med. Res. Rev. 37, 1231–1274.

135. Wei, S.M., and Cherech, D.A. (2011). Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 17, 1359–1370.

136. Barle, L., and Vassalli, G. (2017). Exosomes: therapy delivery tools and biomarkers of diseases. Pharmacol. Ther. 174, 63–78.

137. Taylor, D.D., and Gercel-Taylor, C. (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110, 13–21.

138. Hsu, Y.L., Hung, J.Y., Chang, W.A., Lin, Y.S., Pan, Y.C., Tsai, P.H., Wu, C.Y., and Kuo, P.L. (2017). Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene 36, 4929–4942.

139. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498.

140. Hannon, G.J. (2002). RNA interference. Nature 418, 244–251.

141. Kugeratski, F.G., Hedge, K., Lillà, S., McAndrews, K.M., Zhou, X., Hwang, R.P., Zanivani, S., and Kalluri, R. (2021). Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker. Nat. Cell Biol. 23, 631–641.

142. Kilinc, S., Paisner, R., Camarda, R., Gupta, S., Momcilovic, O., Kohnz, R.A., Arvazouglu, B., L’Etoile, N.D., Perera, R.M., Nomura, D.K., et al. (2021). Oncogene-regulated release of extracellular vesicles. Dev. Cell 56, 1989–2006.e6.

143. Mo, Y., Wang, Y., Zhang, S., Xiong, F., Yan, Q., Jiang, D., Deng, X., Wang, Y., Fan, C., Tang, L., et al. (2021). Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2. Mol. Cancer 20, 112.

144. Li, Y., Al Hallak, M.N., Philip, P.A., Azmi, A.S., and Mohammad, R.M. (2021). Non-coding RNAs in pancreatic cancer diagnostics and therapy: focus on IncRNAs, circRNAs, and piRNAs. Cancers 13, 4161.